Cargando…

Combinatorial bioactive botanicals re-sensitize tamoxifen treatment in ER-negative breast cancer via epigenetic reactivation of ERα expression

Conventional cancer prevention has primarily focused on single chemopreventive compounds that may not be sufficiently efficacious. We sought to investigate potential combinatorial effects of epigenetic bioactive botanicals including epigallocatechin-3-gallate (EGCG) in green tea polyphenols (GTPs) a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Yuanyuan, Meeran, Syed M., Tollefsbol, Trygve O.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5570897/ https://www.ncbi.nlm.nih.gov/pubmed/28839265 http://dx.doi.org/10.1038/s41598-017-09764-3

Ejemplares similares

Synergistic epigenetic reactivation of estrogen receptor-α (ERα) by combined green tea polyphenol and histone deacetylase inhibitor in ERα-negative breast cancer cells
por: Li, Yuanyuan, et al.
Publicado: (2010)

Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer
por: Li, Yuanyuan, et al.
Publicado: (2013)

Bioactive Dietary Supplements Reactivate ER Expression in ER-Negative Breast Cancer Cells by Active Chromatin Modifications
por: Meeran, Syed M., et al.
Publicado: (2012)

A Novel Combinatorial Epigenetic Therapy Using Resveratrol and Pterostilbene for Restoring Estrogen Receptor-α (ERα) Expression in ERα-Negative Breast Cancer Cells
por: Kala, Rishabh, et al.
Publicado: (2016)

Combinatorial epigenetic mechanisms and efficacy of early breast cancer inhibition by nutritive botanicals
por: Li, Yuanyuan, et al.
Publicado: (2016)

Epigenetic targets of bioactive dietary components for cancer prevention and therapy
por: Meeran, Syed M., et al.
Publicado: (2010)

Tamoxifen Action in ER-Negative Breast Cancer
por: Manna, Subrata, et al.
Publicado: (2016)

The Effects of Combinatorial Genistein and Sulforaphane in Breast Tumor Inhibition: Role in Epigenetic Regulation
por: Paul, Bidisha, et al.
Publicado: (2018)

Z-ligustilide restores tamoxifen sensitivity of ERα negative breast cancer cells by reversing MTA1/IFI16/HDACs complex mediated epigenetic repression of ERα
por: Ma, Hui, et al.
Publicado: (2017)

Combinatorial Epigenetics Impact of Polyphenols and Phytochemicals in Cancer Prevention and Therapy
por: Arora, Itika, et al.
Publicado: (2019)

Sulforaphane Causes Epigenetic Repression of hTERT Expression in Human Breast Cancer Cell Lines
por: Meeran, Syed M., et al.
Publicado: (2010)

Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ
por: Mishra, Ameet K., et al.
Publicado: (2016)

Tamoxifen may prevent both ER+ and ER- breast cancers and select for ER- carcinogenesis: an alternative hypothesis
por: Esserman, Laura J, et al.
Publicado: (2005)

Tamoxifen induces hypercoagulation and alterations in ERα and ERβ dependent on breast cancer sub-phenotype ex vivo
por: Pather, K., et al.
Publicado: (2020)

Transcriptomic analysis identifies gene networks regulated by estrogen receptor α (ERα) and ERβ that control distinct effects of different botanical estrogens
por: Gong, Ping, et al.
Publicado: (2014)

TNFα Enhances Tamoxifen Sensitivity through Dissociation of ERα-p53-NCOR1 Complexes in ERα-Positive Breast Cancer
por: Kim, Hyunhee, et al.
Publicado: (2021)

Modulation of transforming growth factor beta expression and induction of apoptosis by tamoxifen in ER positive and ER negative breast cancer cells.
por: Benson, J. R., et al.
Publicado: (1996)

The ERα-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive Breast Cancer
por: Liu, Shu-Shu, et al.
Publicado: (2020)

Mechanisms of Gefitinib-mediated reversal of tamoxifen resistance in MCF-7 breast cancer cells by inducing ERα re-expression
por: Zhang, Xia, et al.
Publicado: (2015)

Systematic integrated analyses of methylomic and transcriptomic impacts of early combined botanicals on estrogen receptor-negative mammary cancer
por: Arora, Itika, et al.
Publicado: (2021)

Estrogen Signaling in ERα-Negative Breast Cancer: ERβ and GPER
por: Girgert, Rainer, et al.
Publicado: (2019)

Nuclear PRMT5 is a biomarker of sensitivity to tamoxifen in ERα (+) breast cancer
por: Poulard, Coralie, et al.
Publicado: (2023)

Tamoxifen-Independent Recombination in the RIP-CreER Mouse
por: Liu, Yanmei, et al.
Publicado: (2010)

ERβ1 Sensitizes and ERβ2 Desensitizes ERα-Positive Breast Cancer Cells to the Inhibitory Effects of Tamoxifen, Fulvestrant and Their Combination with All-Trans Retinoic Acid
por: Meligova, Aggeliki K., et al.
Publicado: (2023)

miR-221/222 sponge abrogates tamoxifen resistance in ER-positive breast cancer cells through restoring the expression of ERα
por: Ouyang, Yan Xiu, et al.
Publicado: (2021)

Aurora-A is a determinant of tamoxifen sensitivity through phosphorylation of ERα in breast cancer
por: Zheng, XQ, et al.
Publicado: (2013)

Neoadjuvant tamoxifen synchronizes ERα binding and gene expression profiles related to outcome and proliferation
por: Severson, Tesa M., et al.
Publicado: (2016)

Estrogen receptor variant ER‐α36 promotes tamoxifen agonist activity in glioblastoma cells
por: Qu, Chao, et al.
Publicado: (2019)

Role of SUMOylation in differential ERα transcriptional repression by tamoxifen and fulvestrant in breast cancer cells
por: Traboulsi, Tatiana, et al.
Publicado: (2018)

Autoantibodies Specific to ERα are Involved in Tamoxifen Resistance in Hormone Receptor Positive Breast Cancer
por: Maselli, Angela, et al.
Publicado: (2019)

Enhancement of Sensitivity to Tamoxifen by Berberine in Breast Cancer Cells by Inhibiting ER-α36 Expression
por: Pan, Xiaohua, et al.
Publicado: (2022)

Genome-Wide Analysis on Transcriptome and Methylome in Prevention of Mammary Tumor Induced by Early Life Combined Botanicals
por: Arora, Itika, et al.
Publicado: (2022)

Stratification of Tamoxifen Synergistic Combinations for the Treatment of ER+ Breast Cancer
por: Zboril, Emily K., et al.
Publicado: (2023)

Extranuclear ERα is associated with regression of T47D PKCα-overexpressing, tamoxifen-resistant breast cancer
por: Perez White, Bethany, et al.
Publicado: (2013)

FEN1 is a prognostic biomarker for ER+ breast cancer and associated with tamoxifen resistance through the ERα/cyclin D1/Rb axis
por: Xu, Lu, et al.
Publicado: (2021)

ER-α36, a Variant of ER-α, Promotes Tamoxifen Agonist Action in Endometrial Cancer Cells via the MAPK/ERK and PI3K/Akt Pathways
por: Lin, Sheng-Li, et al.
Publicado: (2010)

Re-Expression of ERα and AR in Receptor Negative Endocrine Cancers via GSK3 Inhibition
por: Sharma, Vikas, et al.
Publicado: (2022)

Epigenetic regulation of caloric restriction in aging
por: Li, Yuanyuan, et al.
Publicado: (2011)

Tamoxifen Inhibits ER-negative Breast Cancer Cell Invasion and Metastasis by Accelerating Twist1 Degradation
por: Ma, Gang, et al.
Publicado: (2015)

Association of TRPS1 gene with different EMT markers in ERα-positive and ERα-negative breast cancer
por: Su, Peng, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ihi6ei5rhg2e9lqbs2h0cvf8co